home / stock / ocul / ocul news

OCUL News and Press, Ocular Therapeutix Inc.

Stock Information
Company Name: Ocular Therapeutix Inc.
Stock Symbol: OCUL
Market: NASDAQ
Website: ocutx.com
Menu
OCUL OCUL Quote OCUL Short OCUL News OCUL Articles OCUL Message Board
Get OCUL Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUL - Ocular Therapeutix(TM) to Report Second Quarter 2024 Financial Results on August 7, 2024

BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye c...
OCUL - Ocular Therapeutix(TM) Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six months, to 2 mg aflibercept every eight weeks BEDFORD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc....

OCUL - Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

2024-07-23 11:47:46 ET Summary Today, we take a more in-depth look at small-cap biopharma Ocular Therapeutix, Inc. The company is focused on developing therapies for eye conditions using bioresorbable hydrogel-based technology. Ocular's lead clinical candidate, Axpaxli, is und...

OCUL - Ocular Therapeutix(TM) Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative...
OCUL - Ocular Therapeutix(TM) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”, the “Company” ), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovativ...

OCUL - (OCUL) Investment Analysis

2024-06-27 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

OCUL - Ocular Therapeutix jumps as TD Cowen upgrades to Buy and hikes PT

2024-06-20 14:24:06 ET More on Ocular Therapeutix Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results Ocular Therapeutix jumps after investor day updates Ocu...
OCUL - Ocular Therapeutix jumps after investor day updates

2024-06-14 12:58:31 ET More on Ocular Therapeutix Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results Ocular Therapeutix's Impressive Surge: A Strategic Insight ...

OCUL - Ocular Therapeutix(TM) Highlights Exceptional AXPAXLI(TM) SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD 48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm e...

OCUL - (OCUL) Technical Data

2024-06-07 11:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Next 10